These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12097601)

  • 1. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
    Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
    J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
    Schang LM; Rosenberg A; Schaffer PA
    J Virol; 2000 Mar; 74(5):2107-20. PubMed ID: 10666240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
    Schang LM; Phillips J; Schaffer PA
    J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
    Schang LM
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):197-209. PubMed ID: 15023361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
    Schang LM; Rosenberg A; Schaffer PA
    J Virol; 1999 Mar; 73(3):2161-72. PubMed ID: 9971799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
    Diwan P; Lacasse JJ; Schang LM
    J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinases as cellular targets for antiviral drugs.
    Schang LM
    J Antimicrob Chemother; 2002 Dec; 50(6):779-92. PubMed ID: 12460995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
    Schang LM; St Vincent MR; Lacasse JJ
    Antivir Chem Chemother; 2006; 17(6):293-320. PubMed ID: 17249245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
    Schang LM
    Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex viruses in antiviral drug discovery.
    Schang LM
    Curr Pharm Des; 2006; 12(11):1357-70. PubMed ID: 16611120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.
    Schang LM; Coccaro E; Lacasse JJ
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):829-37. PubMed ID: 16248044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs.
    Schang LM
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):29-37. PubMed ID: 15777196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.
    Davido DJ; Von Zagorski WF; Maul GG; Schaffer PA
    J Virol; 2003 Dec; 77(23):12603-16. PubMed ID: 14610183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
    Pumfery A; de la Fuente C; Berro R; Nekhai S; Kashanchi F; Chao SH
    Curr Pharm Des; 2006; 12(16):1949-61. PubMed ID: 16787240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
    Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
    J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.
    Evers DL; Breitenbach JM; Borysko KZ; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2470-6. PubMed ID: 12121920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
    Provencher VM; Coccaro E; Lacasse JJ; Schang LM
    Curr Pharm Des; 2004; 10(32):4081-101. PubMed ID: 15579090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics.
    de la Fuente C; Maddukuri A; Kehn K; Baylor SY; Deng L; Pumfery A; Kashanchi F
    Curr HIV Res; 2003 Apr; 1(2):131-52. PubMed ID: 15043199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
    Chen H; Teng L; Li JN; Park R; Mold DE; Gnabre J; Hwu JR; Tseng WN; Huang RC
    J Med Chem; 1998 Jul; 41(16):3001-7. PubMed ID: 9685239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.
    Davido DJ; Leib DA; Schaffer PA
    J Virol; 2002 Feb; 76(3):1077-88. PubMed ID: 11773384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.